Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial

Richard D. Shell, Katlyn E. McGrattan, Rebecca Hurst-Davis, Sally Dunaway Young, Giovanni Baranello, Arseniy Lavrov, Eamonn O'Brien, Shiri Wallach, Nicole LaMarca, Sandra P. Reyna, Basil T. Darras

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Bulbar function in spinal muscular atrophy has been defined as the ability to meet nutritional needs by mouth while maintaining airway protection and communicate verbally. The effects of disease-modifying treatment on bulbar function are not clear. A multidisciplinary team conducted post-hoc analyses of phase 3 SPR1NT trial data to evaluate bulbar function of infants at risk for spinal muscular atrophy who received one-time gene replacement therapy (onasemnogene abeparvovec) before symptom onset. Three endpoints represented adequate bulbar function in SPR1NT: (1) absence of physiologic swallowing impairment, (2) full oral nutrition, and (3) absence of adverse events indicating pulmonary instability. Communication was not assessed in SPR1NT. We descriptively assessed numbers/percentages of children who achieved each endpoint and all three collectively. SPR1NT included infants <6 postnatal weeks with two (n = 14) or three (n = 15) copies of the survival motor neuron 2 gene. At study end (18 [two-copy cohort] or 24 [three-copy cohort] months of age), 100% (29/29) of patients swallowed normally, achieved full oral nutrition, maintained pulmonary stability, and achieved the composite endpoint. When administered to infants before clinical symptom onset, onasemnogene abeparvovec allowed children at risk for spinal muscular atrophy to achieve milestones within published normal ranges of development and preserve bulbar function.

Original languageEnglish (US)
Pages (from-to)670-676
Number of pages7
JournalNeuromuscular Disorders
Volume33
Issue number8
DOIs
StatePublished - Aug 2023

Bibliographical note

Publisher Copyright:
© 2023

Keywords

  • Airway protection
  • Bulbar function
  • Onasemnogene abeparvovec
  • Oral nutrition
  • Spinal muscular atrophy
  • Swallowing

Fingerprint

Dive into the research topics of 'Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial'. Together they form a unique fingerprint.

Cite this